Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Novel Prognostic Models for Myelodysplastic Syndromes.

Shreve J, Nazha A.

Hematol Oncol Clin North Am. 2020 Apr;34(2):369-378. doi: 10.1016/j.hoc.2019.10.001. Epub 2019 Dec 5. Review.

PMID:
32089216
2.

Large granular lymphocytic laeukemia after solid organ and haematopoietic stem cell transplantation.

Awada H, Mahfouz RZ, Durrani J, Kishtagari A, Jagadeesh D, Lichtin AE, Hill BT, Hamilton BK, Carraway HE, Nazha A, Majhail NS, Sobecks R, Visconte V, Kalaycio M, Sekeres MA, Maciejewski JP.

Br J Haematol. 2020 Jan 20. doi: 10.1111/bjh.16336. [Epub ahead of print]

PMID:
31958160
3.

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.

Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS.

Blood Adv. 2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925.

4.

Does mutational burden add to other prognostic factors in MDS?

Nazha A.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101098. doi: 10.1016/j.beha.2019.101098. Epub 2019 Oct 18. Review.

PMID:
31779975
5.

Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes.

Nagata Y, Makishima H, Kerr CM, Przychodzen BP, Aly M, Goyal A, Awada H, Asad MF, Kuzmanovic T, Suzuki H, Yoshizato T, Yoshida K, Chiba K, Tanaka H, Shiraishi Y, Miyano S, Mukherjee S, LaFramboise T, Nazha A, Sekeres MA, Radivoyevitch T, Haferlach T, Ogawa S, Maciejewski JP.

Nat Commun. 2019 Nov 26;10(1):5386. doi: 10.1038/s41467-019-13001-y.

6.

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.

Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP.

JCO Precis Oncol. 2019;3. doi: 10.1200/po.19.00119. Epub 2019 Sep 20.

7.

Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome.

Durrani J, Awada H, Kishtagari A, Visconte V, Kerr C, Adema V, Nagata Y, Kuzmanovic T, Hong S, Patel B, Nazha A, Lichtin A, Mukherjee S, Saunthararajah Y, Carraway H, Sekeres M, Maciejewski JP.

Leukemia. 2020 Mar;34(3):957-962. doi: 10.1038/s41375-019-0601-y. Epub 2019 Oct 17. No abstract available.

PMID:
31624375
8.

Genomics of therapy-related myeloid neoplasms.

Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, Przychodzen BP, Jha BK, Hiwase D, Singhal D, Advani AS, Nazha A, Gerds AT, Carraway HE, Sekeres MA, Mukherjee S, Maciejewski JP, Radivoyevitch T.

Haematologica. 2020 Mar;105(3):e98-e101. doi: 10.3324/haematol.2019.219352. Epub 2019 Aug 14. No abstract available.

9.

Distinct clinical and biological implications of CUX1 in myeloid neoplasms.

Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, Maciejewski JP.

Blood Adv. 2019 Jul 23;3(14):2164-2178. doi: 10.1182/bloodadvances.2018028423.

10.

Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?

Madanat YF, Kalaycio ME, Nazha A.

Acta Med Acad. 2019 Apr;48(1):35-44. doi: 10.5644/ama2006-124.240. Review.

11.

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.

Advani AS, Cooper B, Visconte V, Elson P, Chan R, Carew J, Wei W, Mukherjee S, Gerds A, Carraway H, Nazha A, Hamilton B, Sobecks R, Caimi P, Tomlinson B, Malek E, Little J, Miron A, Pink J, Maciejewski J, Unger A, Kalaycio M, de Lima M, Sekeres MA.

Clin Cancer Res. 2019 Jul 15;25(14):4231-4237. doi: 10.1158/1078-0432.CCR-18-3886. Epub 2019 Apr 16.

12.

Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure.

Shen W, Kerr CM, Przychozen B, Mahfouz RZ, LaFramboise T, Nagata Y, Hanna R, Radivoyevitch T, Nazha A, Sekeres MA, Maciejewski JP.

Br J Haematol. 2019 Jun;185(5):935-939. doi: 10.1111/bjh.15862. Epub 2019 Mar 19.

PMID:
30891747
13.

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.

Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, Maciejewski JP.

Blood Adv. 2019 Feb 12;3(3):339-349. doi: 10.1182/bloodadvances.2018024216.

14.

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.

Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M, Sekeres MA, Sobecks R, de Lima M, Majhail NS, Maciejewski J.

Bone Marrow Transplant. 2019 Aug;54(8):1281-1286. doi: 10.1038/s41409-019-0444-1. Epub 2019 Jan 17.

PMID:
30655603
15.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

16.

BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes.

Abuhadra N, Mukherjee S, Al-Issa K, Adema V, Hirsch CM, Advani A, Przychodzen B, Makhoul A, Awada H, Maciejewski JP, Sekeres MA, Nazha A.

Leuk Lymphoma. 2019 Jun;60(6):1587-1590. doi: 10.1080/10428194.2018.1543885. Epub 2019 Jan 8. No abstract available.

PMID:
30618304
17.

The MDS genomics-prognosis symbiosis.

Nazha A.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):270-276. doi: 10.1182/asheducation-2018.1.270. Review.

18.

Online and Social Media Resources for Patients with MDS.

Abuhadra N, Nazha A.

Curr Hematol Malig Rep. 2018 Dec;13(6):570-575. doi: 10.1007/s11899-018-0486-2. Review.

PMID:
30306313
19.

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.

Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S.

Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21. No abstract available.

20.

Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Nazha A, Patnaik MM.

Curr Hematol Malig Rep. 2018 Oct;13(5):341-347. doi: 10.1007/s11899-018-0465-7. Review.

PMID:
30066099
21.

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.

Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G.

Am J Hematol. 2018 Oct;93(10):1245-1253. doi: 10.1002/ajh.25234. Epub 2018 Sep 26.

22.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

23.

Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

PMID:
29795413
24.

Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.

Molenaar RJ, Sidana S, Radivoyevitch T, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1889-1892. doi: 10.1200/JCO.2018.78.4074. Epub 2018 May 3. No abstract available.

PMID:
29723096
25.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.

Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS.

Blood Cancer J. 2018 Jan 10;8(1):4. doi: 10.1038/s41408-017-0040-9.

26.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1831-1839. doi: 10.1200/JCO.2017.75.0232. Epub 2017 Dec 18.

PMID:
29252123
27.

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G.

Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7. No abstract available.

28.

Impact of social media for the hematologist/oncologist.

Abuhadra N, Majhail NS, Nazha A.

Semin Hematol. 2017 Oct;54(4):193-197. doi: 10.1053/j.seminhematol.2017.07.003. Epub 2017 Sep 18. Review.

PMID:
29153080
29.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S.

Leukemia. 2018 Apr;32(4):952-959. doi: 10.1038/leu.2017.323. Epub 2017 Nov 6.

PMID:
29104287
30.

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Visconte V, Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, Maciejewski JP.

Leukemia. 2018 Feb;32(2):550-553. doi: 10.1038/leu.2017.295. Epub 2017 Sep 22. No abstract available.

PMID:
28935992
31.

Origins of myelodysplastic syndromes after aplastic anemia.

Negoro E, Nagata Y, Clemente MJ, Hosono N, Shen W, Nazha A, Yoshizato T, Hirsch C, Przychodzen B, Mahfouz RZ, Kuzmanovic T, Sekeres MA, Makishima H, Ogawa S, Maciejewski JP.

Blood. 2017 Oct 26;130(17):1953-1957. doi: 10.1182/blood-2017-02-767731. Epub 2017 Sep 11. No abstract available.

32.

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, Maciejewski JP, Sekeres MA.

Blood Cancer J. 2017 Sep 1;7(9):e602. doi: 10.1038/bcj.2017.82. No abstract available.

33.

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.

Nazha A, Bejar R.

Curr Hematol Malig Rep. 2017 Oct;12(5):461-467. doi: 10.1007/s11899-017-0407-9. Review.

PMID:
28844082
34.

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA.

Leukemia. 2017 Dec;31(12):2848-2850. doi: 10.1038/leu.2017.266. Epub 2017 Aug 18. No abstract available.

PMID:
28819282
35.

Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).

Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG 2nd, Jerez A, Thota S, Patel B, Hirsch C, Nazha A, Desamito J, Lichtin A, Pohlman B, Sekeres MA, Radivoyevitch T, Maciejewski JP.

Leuk Lymphoma. 2018 Feb;59(2):416-422. doi: 10.1080/10428194.2017.1339880. Epub 2017 Jun 20.

PMID:
28633612
36.

Genomic determinants of chronic myelomonocytic leukemia.

Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, Clemente M, Hirsch C, Morawski A, Souaid R, Saygin C, Nazha A, Demarest B, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Ogawa S, Makishima H, Sekeres MA, Maciejewski JP.

Leukemia. 2017 Dec;31(12):2815-2823. doi: 10.1038/leu.2017.164. Epub 2017 May 30.

PMID:
28555081
37.

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP.

J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.

38.

Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.

Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega JR, Wang J, Nazha A, Chen L, Yao B, Liu C, Chen S, Weeks O, Ni H, Phillips BL, Huang S, Wang J, He C, Li GM, Radivoyevitch T, Aifantis I, Maciejewski JP, Yang FC, Jin P, Xu M.

Nat Commun. 2017 Apr 25;8:15102. doi: 10.1038/ncomms15102.

39.

Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.

Patel SS, Sekeres MA, Nazha A.

Leuk Lymphoma. 2017 Nov;58(11):2532-2539. doi: 10.1080/10428194.2017.1307361. Epub 2017 Mar 28. Review.

PMID:
28351181
40.

Molecular features of early onset adult myelodysplastic syndrome.

Hirsch CM, Przychodzen BP, Radivoyevitch T, Patel B, Thota S, Clemente MJ, Nagata Y, LaFramboise T, Carraway HE, Nazha A, Sekeres MA, Makishima H, Maciejewski JP.

Haematologica. 2017 Jun;102(6):1028-1034. doi: 10.3324/haematol.2016.159772. Epub 2017 Mar 2.

41.

Molecular landscape in acute myeloid leukemia: where do we stand in 2016.

Al-Issa K, Nazha A.

Cancer Biol Med. 2016 Dec;13(4):474-482. doi: 10.20892/j.issn.2095-3941.2016.0061.

42.

Driving After Microinvasive Total Hip Arthroplasty.

Qurashi S, Chinnappa J, Lord SJ, Nazha A, Gordon J, Chow J.

J Arthroplasty. 2017 May;32(5):1525-1529. doi: 10.1016/j.arth.2016.11.052. Epub 2016 Dec 20.

PMID:
28057395
43.

The complexity of interpreting genomic data in patients with acute myeloid leukemia.

Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway HE, Hirsch CM, Przychodzen B, Patel BJ, Clemente M, Sanikommu SR, Kalaycio M, Maciejewski JP, Sekeres MA.

Blood Cancer J. 2016 Dec 16;6(12):e510. doi: 10.1038/bcj.2016.115.

44.

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA.

Leukemia. 2016 Nov;30(11):2214-2220. doi: 10.1038/leu.2016.138. Epub 2016 May 20.

PMID:
27311933
45.

Chronic Abdominal Wall Pain.

Russo M, Volschenk W, Nazha A, Santarelli D.

J Clin Gastroenterol. 2019 Mar;53(3):e129-e130. doi: 10.1097/MCG.0000000000000732. No abstract available.

PMID:
27775959
46.

GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.

Nazha A, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill BT, Kalaycio M, Liu H, Pohlman B, Sobecks R, Sekeres MA, Majhail NS.

Bone Marrow Transplant. 2016 Dec;51(12):1642-1643. doi: 10.1038/bmt.2016.254. Epub 2016 Oct 10. No abstract available.

PMID:
27721371
47.

Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations.

Nazha A, Sekeres MA.

Annu Rev Med. 2017 Jan 14;68:127-137. doi: 10.1146/annurev-med-062915-095637. Epub 2016 Sep 7. Review.

PMID:
27618752
48.

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP.

Leukemia. 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. Epub 2016 Aug 18. No abstract available.

49.

Improving Prognostic Modeling in Myelodysplastic Syndromes.

Nazha A, Sekeres MA.

Curr Hematol Malig Rep. 2016 Dec;11(6):395-401. doi: 10.1007/s11899-016-0342-1. Review.

PMID:
27502092
50.

Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?

Nazha A, Khoury JD, Verstovsek S, Daver N.

Crit Rev Oncol Hematol. 2016 Sep;105:112-7. doi: 10.1016/j.critrevonc.2016.06.013. Epub 2016 Jun 26. Review.

PMID:
27401783

Supplemental Content

Support Center